Previous reports have shown that the therapeutic use of IFN-a, a major type I IFN family member, can induce an SLE-like syndrome, while blocking the action of type I IFNs or their common receptor reduces immunological dysfunction and decreases tissue damage in SLE [13–16]. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.